Tag : UNRESECTABLE EMBOLIZATION-ELIGIBLE HEPATOCELLULAR CARCINOMA

CONFERENCE UPDATE

STRIDE + lenvatinib + TACE significantly improves PFS in unresectable eeHCC: Phase 3 EMERALD-3 trial
EMERALD-3 demonstrated that STRIDE + lenvatinib + TACE significantly improved PFS compared with TACE alone in unresectable embolization-eligible hepatocellular carcinoma. The regimen also showed a favorable OS trend, improved tumor response, and a manageable safety profile, supporting its potential as a new treatment option.